HC Wainwright Reaffirms “Neutral” Rating for Eyenovia (NASDAQ:EYEN)

HC Wainwright reaffirmed their neutral rating on shares of Eyenovia (NASDAQ:EYEN) in a research note released on Friday morning,Benzinga reports. HC Wainwright currently has a $2.00 price objective on the stock.

Eyenovia Stock Down 4.2 %

EYEN opened at $1.38 on Friday. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.58. Eyenovia has a 1-year low of $1.28 and a 1-year high of $124.80. The company has a market capitalization of $1.92 million, a PE ratio of -0.02 and a beta of 1.29. The firm’s 50 day simple moving average is $2.66 and its two-hundred day simple moving average is $17.98.

Institutional Trading of Eyenovia

An institutional investor recently raised its position in Eyenovia stock. Geode Capital Management LLC increased its position in shares of Eyenovia, Inc. (NASDAQ:EYEN) by 36.6% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 557,994 shares of the company’s stock after purchasing an additional 149,471 shares during the period. Geode Capital Management LLC owned 0.87% of Eyenovia worth $288,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 25.84% of the company’s stock.

Eyenovia Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.